Efpegsomatropin - Hanmi Pharmaceutical

Drug Profile

Efpegsomatropin - Hanmi Pharmaceutical

Alternative Names: HM-10560A; LAPS-hGH; LAPS-rhGH

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Somatotropin deficiency

Most Recent Events

  • 30 Aug 2017 Phase-II development is ongoing in Somatotropin deficiency (Hanmi Pharmaceutical pipeline, August 2017)
  • 13 Mar 2015 Phase-II clinical trials in Somatotropin deficiency in Ukraine, Serbia, Russia, Romania, India, Bulgaria and South Korea (SC) after October 2011 (EudraCT2011-001826-61)
  • 06 Feb 2014 Hanmi Pharmaceutical completes enrolment in its phase II trial for Somatotropin deficiency in Hungary (NCT01822340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top